General Research
Model: human
The Effects of Hydrogen Gas Inhalation on Adverse Left Ventricular Remodeling After Percutaneous Coronary Intervention for ST-Elevated Myocardial Infarction – First Pilot Study in Humans
Simplified Version Available
Healing Hearts with Hydrogen: How Gas Inhalation Can Aid Recovery After Heart Attack
A 2017 study published in the Circulation Journal found that inhaling hydrogen gas after a heart attack and a procedure called percutaneous coronary intervention (PCI) may reduce the risk of adverse left ventricular remodeling, leading to better heart health. This simple and non-invasive treatment offers hope for improving outcomes for patients who have suffered a heart attack. More research is needed, but the potential benefits of hydrogen therapy are promising.
Read Simplified ArticleAbstract
Publish Year 2017 Country Japan Rank Positive Journal Circulation Journal Primary Topic Heart Secondary TopicSurgery/Transplantation Model Human Tertiary TopicAngioplasty Vehicle Gas pH N/A Application Inhalation Comparison Complement
Background
Results:The 20 patients with an initial diagnosis of STEMI were assigned to either an HI group (1.3% H2with 26% oxygen) or a control group (26% oxygen). There were no HI-related severe adverse events. In the full analysis set, the cardiac salvage index as evaluated using cardiac magnetic resonance imaging at 7 days after primary percutaneous coronary intervention (PCI), showed no significant between-group difference (HI: 50.0±24.3%; control: 60.1±20.1%; P=0.43). However, the improvement from day 7 in the HI group was numerically greater than that in the control group in some of the surrogate outcomes at 6-month follow-up, including the LV stroke volume index (HI: 9.2±7.1 mL/m2; control: -1.4±7.2 mL/m2; P=0.03) and the LV ejection fraction (HI: 11.0%±9.3%; control: 1.7%±8.3%; P=0.11). Conclusions: The first clinical study has shown that HI during PCI is feasible and safe and may also promote LV reverse remodeling at 6 months after STEMI. The study was not powered to test efficacy and a further large-scale trial is warranted. (Clinical trials registration: UMIN00006825).